Prognosis evaluation and follow-up of resistant trophoblastic neoplasia.

doi:10.7504/fk2015020111

Abstract

Abstract:

Abstract:Although most patients with gestational trophoblastic neoplasms have optimistic prognosis due to their sensitivity to the chemotherapy, approximately ten to twenty-five percent of them might develop resistance to the primary chemotherapy.The present article gives a brief introduction to evaluating the prognosis and follow-up of the resistant gestational trophoblastic neoplasms.

Key words: gestational trophoblastic neoplasms, resistant, prognosis, follow-up

摘要：

绝大多数滋养细胞肿瘤对化疗极为敏感，因此预后较好，但仍有大约10%～25%的滋养细胞肿瘤患者对化疗耐药。由于耐药性滋养细胞肿瘤的发生率不高，对其认识有限。文章主要着重从预后评估和随访方面对耐药性滋养细胞肿瘤做一阐述。

关键词: 妊娠滋养细胞肿瘤, 耐药, 预后, 随访

CLC Number:

R737.3

ZHAO Jun,XIANG Yang.. Prognosis evaluation and follow-up of resistant trophoblastic neoplasia.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015020111.

赵峻，向阳. 耐药性滋养细胞肿瘤预后评估及随访[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2015020111.

References

［1］    向阳.宋鸿钊滋养细胞肿瘤学［M］.3版.北京:人民卫生出版社,2011：301.

［2］   Lurain JR.Gestational trophoblastic disease Ⅱ: classification and management of gestational trophoblastic neoplasia［J］.Am J Obstet Gynecol,2011，204(1):11-18.

［3］   Wang J, Short D, Sebire NJ,et al.Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE) ［J］.Ann Oncol，2008，19(9):1578-1583.

［4］   Feng F, Xiang Y, Li L, et al.Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia［J］.Gynecol Oncol，2009，113(3):312-315.

［5］   Zhao J, Xiang Y，Wan XR, et al.Molecular genetic analyses of Choriocarcinoma［J］.Placenta，2009,30(9):816-820.

［6］   Alifrangis C, Agarwal R, Short D,et al.EMA-CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis［J］.J Clin Oncol，2013，31(2):280-286.

［7］   Kingdon SJ, Coleman RE, Ellis L,et al.Deaths from gestational trophoblastic neoplasia: any lessons to be learned? ［J］.J Reprod Med，2012 ，57(7-8):293-296.

［8］   Patel SM, Desai A.Management of drug resistant gestational trophoblastic neoplasia［J］.J Reprod Med，2010，55(7-8):296-300.

［9］    周莹，冯凤芝，向阳，等.耐药和复发性妊娠滋养细胞肿瘤的临床病例分析［J］.中华妇产科杂志，2010，45（11）：804-807.

［10］    Alazzam M, Tidy J, Osborne R,et al.Chemtherapy for resistant or recurrent gestational trophoblastic neoplasia［J］.Cochrane Database Syst Rev，2012，12:CD008891.doi: 10.1002/14651858.CD008891.pub2.

[1]	CHENG Guang-yan, QU Peng-peng.. Standardized management of hydatidiform mole. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(7): 684-687.
[2]	ZHANG Qing-quan, WANG Shi-jun. Quality control of surgery for endometrial cancer. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(1): 25-27.
[3]	. [J]. Acta Metallurgica Sinica, 2021, 37(7): 731-739.
[4]	XU Huang-fang，LI Xiao-tian. Risk and prevention of long-term cardiovascular diseases and other diseases in preeclampsia. [J]. Acta Metallurgica Sinica, 2021, 37(2): 142-145.
[5]	HUANG He，LIU Ji-hong. Standardization of postoperative adjuvant treatment for cervical cancer. [J]. Acta Metallurgica Sinica, 2021, 37(1): 51-54.
[6]	TAN Hu，CHEN Dun-jin. Clinical diagnosis of fetal growth restriction. [J]. Acta Metallurgica Sinica, 2020, 36(8): 695-698.
[7]	WANG Wei，LIU Cong-rong. Clinicopathological significance of Silva pattern system in cervical adenocarcinoma and related research progress. [J]. Acta Metallurgica Sinica, 2020, 36(7): 596-601.
[8]	CHEN Jing，LIU Mu-biao. Standardized management and follow-up of cervical low-grade squamous intraepithelial lesion. [J]. Acta Metallurgica Sinica, 2020, 36(7): 601-604.
[9]	GAO Shu-jun，SUI Long. Standardized management and follow-up of cervical high-grade squamous intraepithelial lesion. [J]. Acta Metallurgica Sinica, 2020, 36(7): 604-608.
[10]	ZHANG Shi-qian，YUAN Hang. Fertility-sparing treatment for early stage epithelial ovarian cancer. [J]. Acta Metallurgica Sinica, 2019, 35(6): 623-626.
[11]	. [J]. Acta Metallurgica Sinica, 2018, 34(7): 755-757.
[12]	LIU Ji-hong，HUANG He. Role of pelvic exenteration in the treatment of recurrent cervical cancer. [J]. Acta Metallurgica Sinica, 2018, 34(11): 1223-1226.
[13]	HUANG He，LIU Ji-hong. Knowing carcinosarcoma of the female genital tract [J]. Acta Metallurgica Sinica, 2017, 33(4): 338-342.
[14]	ZHU Jun，WU Xiao-hua. How to improve the curative effect on ovarian carcinosarcoma [J]. Acta Metallurgica Sinica, 2017, 33(4): 357-360.
[15]	LIN Zhong-qiu,WANG Li-juan,LI Rui-xin.. Neoadjuvant chemotherapy in vulvar cancer: current status and future diretions. [J]. Acta Metallurgica Sinica, 2016, 32(9): 845-848.